| Literature DB >> 35094296 |
Babak Pakbin1, Shaghayegh Pishkhan Dibazar2, Samaneh Allahyari3, Maryam Javadi4, Zahra Amani1, Alireza Farasat5, Sina Darzi6.
Abstract
Saccharomyces boulardii, a variety of S. cerevisiae, is used as a probiotic yeast in food and drug industries. However, S. boulardii is an opportunistic pathogen, and the supernatant of this organism has recently been recommended for its health-promoting benefits. Breast cancer is the most frequent cancer disease in women worldwide. The objective of this study was to investigate the effects of S. boulardii supernatant (SBS) on cell viability, inducing apoptosis and suppression of survivin gene expression in MCF-7 and MCF-7/MX as human non-drug-resistant and multidrug-resistant breast cancer cells respectively. The IC50 value of SBS against MCF-7 was calculated 1037, 542, and 543 µg/mL for 24, 48, and 72 h treatments, respectively. Also, this value against MCF-7/MX cells were measured 1242, 616, and 444 µg/mL after 24, 48, and 72 h respectively. We found that suppression of survivin gene expression should be one of the main molecular antitumor mechanisms which is contributed to apoptosis in breast cancer cells. However, anticancer activity of SBS was observed more efficient against MCF-7 than that against MCF-7/MX cells. SBS is suggested to be considered as one of the prospective anticancer drugs to treat human breast carcinoma. More investigations especially in vivo studies are strongly recommended to be implemented to characterize other antitumor mechanisms of SBS against breast carcinoma.Entities:
Keywords: Anticancer properties; Breast carcinoma; In vitro study; Probiotic Saccharomyces boulardii; Yeast supernatant
Year: 2022 PMID: 35094296 DOI: 10.1007/s12602-021-09756-w
Source DB: PubMed Journal: Probiotics Antimicrob Proteins ISSN: 1867-1306 Impact factor: 4.609